Johnson & Johnson ($JNJ) was aware of the alarming failure rates of ASR hip implants a year before the company stopped making them and two years before they were recalled, newly unsealed court documents show. Report | Report (sub. req.)
| Download Today | Sponsored by: BaxterWhile the development of an aqueous solution formulation may be preferred over a lyophilized product, it is useful to initially pursue a dual path and develop drug product formulations for both a sterile solution and a freeze-dried solid presentation. Learn More Today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!